Mepivacaïne Hcl B. Braun (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. By preventing sodium influx, the drug stops the generation and propagation of action potentials, resulting in a reversible loss of sensation in the area where it is administered.

The dose of Mepivacaïne Hcl B. Braun is determined by the prescribing clinician based on the type of procedure, patient weight, age, and clinical condition. Only a qualified health professional should calculate and administer the appropriate amount.

Safety data for mepivacaine during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mepivacaine is an amide‑type local anesthetic with a rapid onset and intermediate duration, similar to lidocaine but with slightly longer sensory block and less vasodilatory effect. This can reduce the need for added vasoconstrictors in some procedures, offering a useful alternative when a longer block is desired.

The product should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperatures. Do not freeze the solution, and handle it with aseptic technique to maintain sterility.

Mepivacaïne Hcl B. Braun is administered by a qualified health professional via injection into the epidural space or around a peripheral nerve. The injection is performed under sterile conditions, often using a needle or catheter, and the volume injected is tailored to the specific clinical need.

Serious adverse events include allergic reactions such as anaphylaxis, cardiovascular collapse or severe arrhythmias, central nervous system toxicity leading to seizures, prolonged motor block, and rare cases of methemoglobinemia. Immediate medical attention is required if any of these symptoms occur.

Patients with a known hypersensitivity to mepivacaine, other amide‑type local anesthetics, or any component of the formulation should not receive the drug. It is also contraindicated in individuals with severe cardiac conduction disorders or uncontrolled epilepsy, unless a specialist determines that benefits outweigh risks.